Evommune (EVMN) Leases (2024 - 2026)

Name: Evommune (EVMN) Leases (2024 - 2026) | Business Quant
Creator: Business Quant

Evommune (EVMN) reported Leases of $7.9 million for Q1 2026, up 439.82% on a QoQ basis from $1.5 million in Q4 2025.

Evommune (EVMN) has 3 years of Leases data on file, last reported at $7.9 million in Q1 2026.

Quarterly Leases changed N/A year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, up 211.23% from the prior year.
Leases improved to $7.9 million in Q1 2026 per EVMN's latest filing, from $1.5 million in the prior quarter.
Across five years, Leases topped out at $7.9 million in Q1 2026 and bottomed at $160000.0 in Q3 2025.
The 3-year median for Leases is $970500.0 (2024), against an average of $2.5 million.
Peak annual rise in Leases reached 211.23% in 2025, while the deepest fall reached 211.23% in 2025.
Tracing EVMN's Leases over 3 years: stood at $472000.0 in 2024, then surged by 211.23% to $1.5 million in 2025, then soared by 439.82% to $7.9 million in 2026.
Per Business Quant, the three latest EVMN Leases figures stand at $7.9 million (Q1 2026), $1.5 million (Q4 2025), and $160000.0 (Q3 2025).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Leases (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	83,048.00
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	61,822.50
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	285.20 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	1.69 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	-
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	189.30 Mn
10	Evommune	744.11 Mn	532.65 Mn	-	7.93 Mn

Download Data 🔒